Summary
0Y6X Chart
Medtronic: Solid Recent Performance But Better Options Available
Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind peers like Johnson & Johnson and Stryker. Despite a solid 2025 performance, the stock's recent gains stem from a low base, and it still trades well below its 2021 highs. Earnings growth is steady but uninspiring, with margin pressure and tariff risks highlighting operational challenges versus higher-quality competitors.
Medtronic announces MiniMed as name for planned New Diabetes Company
GALWAY, Ireland , June 12, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world.
Medtronic Announces Intent To Spin Diabetes Business
Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.
Medtronic plc Dividends
 0Y6X 2 months ago | Other | $0.7 Per Share |
| 0Y6X 5 months ago | Other | $0.7 Per Share |
| 0Y6X 8 months ago | Other | $0.7 Per Share |
| 0Y6X 11 months ago | Other | $0.7 Per Share |
| 0Y6X 21 Mar 2024 | Other | $0.69 Per Share |
Medtronic plc Earnings
| 19 Aug 2025 (63 Days) Date | | - Cons. EPS | - EPS |
| 22 May 2025 Date | | - Cons. EPS | - EPS |
| 21 May 2025 Date | | - Cons. EPS | 0.82 EPS |
| 18 Feb 2025 Date | | - Cons. EPS | 1.01 EPS |
| 19 Nov 2024 Date | | - Cons. EPS | 0.99 EPS |
| 0Y6X 2 months ago | Other | $0.7 Per Share |
| 0Y6X 5 months ago | Other | $0.7 Per Share |
| 0Y6X 8 months ago | Other | $0.7 Per Share |
| 0Y6X 11 months ago | Other | $0.7 Per Share |
| 0Y6X 21 Mar 2024 | Other | $0.69 Per Share |
| 19 Aug 2025 (63 Days) Date | | - Cons. EPS | - EPS |
| 22 May 2025 Date | | - Cons. EPS | - EPS |
| 21 May 2025 Date | | - Cons. EPS | 0.82 EPS |
| 18 Feb 2025 Date | | - Cons. EPS | 1.01 EPS |
| 19 Nov 2024 Date | | - Cons. EPS | 0.99 EPS |
Medtronic plc (0Y6X) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Medtronic plc ever had a stock split?
Medtronic plc Profile
| Medical - Devices Industry | Healthcare Sector | Mr. Geoffrey Straub Martha CEO | LSE Exchange | IE00BTN1Y115 ISIN |
| IE Country | 95,000 Employees | 27 Jun 2025 Last Dividend | 27 Sep 1999 Last Split | 13 Jan 1978 IPO Date |
Overview
Medtronic plc is a global leader in medical technology, specializing in the development, manufacture, and sale of device-based medical therapies. Serving healthcare systems, physicians, clinicians, and patients around the world, the company is dedicated to alleviating pain, restoring health, and extending life for millions of people. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic operates across various medical domains through its diverse portfolio which includes cardiovascular, medical surgical, neuroscience, and diabetes treatments and technologies.
Products and Services
Medtronic’s comprehensive range of products and services is categorized into four primary segments:
- Cardiovascular Portfolio: This segment offers advanced device-based solutions for cardiac care, including:
- Implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices for heart rhythm management.
- Cardiac ablation products for treating atrial fibrillation.
- Insertable cardiac monitor systems for continuous heart monitoring.
- TYRX products, which involve antimicrobial envelopes for electronic implantable devices.
- Aortic valves, surgical valve replacement and repair products, transcatheter pulmonary valves, and endovascular stent grafts for structural heart disease treatment.
- Percutaneous coronary intervention products and angioplasty balloons for coronary artery disease treatment.
- Remote monitoring and patient-centered software for enhanced patient care.
- Medical Surgical Portfolio: This segment encompasses a broad array of surgical instruments and devices, including:
- Surgical stapling devices and vessel sealing instruments for precise surgical procedures.
- Wound closure products and electrosurgery products aimed at efficient surgical recovery.
- Surgical artificial intelligence and robotic-assisted surgery products for advanced surgical techniques.
- Hernia mechanical devices and mesh implants, along with other gynecology and lung health products.
- Minimally invasive gastrointestinal and hepatologic diagnostic and therapy tools, patient monitoring, airway management and ventilation therapies, and renal disease treatments.
- Neuroscience Portfolio: This segment delivers solutions for the central nervous system and supportive structures, including:
- Products for spinal, neuro, and orthopedic surgeries, pain management, and urology.
- Energy surgery instruments and image-guided surgery systems for enhanced surgical accuracy.
- Intra-operative imaging and robotic guidance systems for spine procedures.
- Therapies for brain vasculature conditions.
- Diabetes Operating Unit: Focused on diabetes management, this segment offers:
- Insulin pumps and consumables for continuous insulin delivery.
- Continuous glucose monitoring systems for real-time blood glucose tracking.
- Smart insulin pen systems and related consumables for modern diabetes care.
Contact Information
